Skip to content

Clinical trials

Phase 2 Carcinoma, Non-Small-Cell Lung trials in the United Kingdom

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Carcinoma, Non-Small-Cell Lung Phase: Phase 2 Country / region: United Kingdom Clear all

109 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20021
20035
20041
20051
20064
20072
20085
20096
20104
20116
20127
20137
20145
201510
20161
20176
20184
20194
20201
20215
20225
20235
20244
20252
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed66
Terminated15
Active, not recruiting13
Recruiting8
Unknown status5
Not yet recruiting1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Bristol-Myers Squibb9
Eli Lilly and Company9
Novartis Pharmaceuticals7
Hoffmann-La Roche6
European Organisation for Research and Treatment of Cancer - EORTC5
GlaxoSmithKline5
AstraZeneca4
ETOP IBCSG Partners Foundation4
University College, London4
Pfizer3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Carcinoma, Non-Small-Cell Lung109
Lung Neoplasms26
Melanoma11
Neoplasm Metastasis9
Neoplasms7
Ovarian Neoplasms6
Pancreatic Neoplasms6
Squamous Cell Carcinoma of Head and Neck6
Adenocarcinoma of Lung5
Breast Neoplasms5

Trials

Showing 1 to 25 of 109. Each trial links to its page on Pharma Observatory.

9 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.